Intellia Therapeutics (United States)

Recent papers from Intellia Therapeutics (United States)

1. CAA-X V5.1 Robot Extension (CAA-R): Modular Control for Embodied Agents — Revised and Expanded Edition2026
2. CAA-X V7.1 Future Architectures and the K4–K5 Roadmap: Beyond Current Paradigms — Revised and Expanded Edition2026
3. CAA-X V6.1 Cognitive-Physical Fusion (CAA-X-CP): Unifying Mind and Matter through Field Theory — Revised and Expanded Edition2026
4. CAA-X V3.1 Intention is All You Need: A Manifesto for Goal-Driven AI — Revised and Expanded Edition2026
5. CAA-X 2.0 (V9): Structural Completeness for Socially-Embedded Agency via Dual Aspect Surprise Minimization2026
6. CAA-X V2.1: Cognitive Physicalism2026
7. CAA-X-B (V8): A Research Agenda for Modular Brain-Computer Interface Architectures2026
8. CAA-X V10: The Evolutionary Distillation of Intelligence and the Cognitive Primitives Library2026
9. CAA-X V5: CAA-R – Robotic Extension2026
10. CAA-X V6: Cognitive Physics Fusion2026
11. CAA-X V7: Architectural Opportunities for Next-Generation Large Models2026
12. CAA-X V3: Intention is All You Need — A Manifesto for Goal-Driven AI2026
13. CAA-X V0–V2 Collection: Cognitive Atom Architecture — From Foundational Theory to Embodied AI2026
14. CAA-X V4: World Models and Action Generation2026
15. CAA-X V3: Intention is All You Need — A Manifesto for Goal-Driven AI2026
16. 17P Single-cell profiling guides a disease-tailored TCR-based immunotherapy for epithelial ovarian cancerESMO Open · 2026
17. Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary AngioedemaNew England Journal of Medicine · 2026
18. CAA-X V4: Cognitive Architecture eXtension for Zero-Shot Agent Challenges2026
19. Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome EditingHuman Gene Therapy · 2026
20. Defective BRCA1-mediated DNA end resection drives tandem duplication formation and FANCM synthetic lethality2026